Canada
· Delayed Price · Currency is CAD Bright Minds Biosciences Statistics
Total Valuation
Bright Minds Biosciences has a market cap or net worth of CAD 250.51 million. The enterprise value is 244.33 million.
| Market Cap | 250.51M |
| Enterprise Value | 244.33M |
Important Dates
The next estimated earnings date is Friday, December 27, 2024.
| Earnings Date | Dec 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Bright Minds Biosciences has 4.46 million shares outstanding. The number of shares has increased by 19.17% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.46M |
| Shares Change (YoY) | +19.17% |
| Shares Change (QoQ) | +4.15% |
| Owned by Insiders (%) | 33.43% |
| Owned by Institutions (%) | 6.53% |
| Float | 647,107 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 41.07 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -68.24 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 35.08, with a Debt / Equity ratio of 0.00.
| Current Ratio | 35.08 |
| Quick Ratio | 34.75 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -536.87 |
Financial Efficiency
Return on equity (ROE) is -51.80% and return on invested capital (ROIC) is -30.53%.
| Return on Equity (ROE) | -51.80% |
| Return on Assets (ROA) | -28.86% |
| Return on Capital (ROIC) | -30.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +3,331.95% in the last 52 weeks. The beta is 1.73, so Bright Minds Biosciences's price volatility has been higher than the market average.
| Beta (5Y) | 1.73 |
| 52-Week Price Change | +3,331.95% |
| 50-Day Moving Average | 31.32 |
| 200-Day Moving Average | 9.10 |
| Relative Strength Index (RSI) | 52.23 |
| Average Volume (20 Days) | 14,412 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.40M |
| Pretax Income | -3.58M |
| Net Income | -3.58M |
| EBITDA | n/a |
| EBIT | -3.40M |
| Earnings Per Share (EPS) | -0.87 |
Balance Sheet
The company has 6.19 million in cash and 14,016 in debt, giving a net cash position of 6.18 million or 1.38 per share.
| Cash & Cash Equivalents | 6.19M |
| Total Debt | 14,016 |
| Net Cash | 6.18M |
| Net Cash Per Share | 1.38 |
| Equity (Book Value) | 6.10M |
| Book Value Per Share | 1.37 |
| Working Capital | 6.09M |
Cash Flow
| Operating Cash Flow | -2.58M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bright Minds Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.17% |
| Shareholder Yield | -19.17% |
| Earnings Yield | -1.54% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on July 14, 2023. It was a reverse split with a ratio of 0.2.
| Last Split Date | Jul 14, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |